77results about How to "Lower survival rate" patented technology

The invention belongs to the field of biomedicines, and relates to applications of chrysophanol or a derivative thereof and oncolytic virus in preparation of antitumor drugs. The invention finds that chrysophanol or the derivative thereof can be used for preparing oncolytic virus antitumor synergistic agents for the first time. Meanwhile, the invention also relates to a pharmaceutical composition containing chrysophanol and oncolytic virus, a medicine suit containing chrysophanol and oncolytic virus, and applications of chrysophanol and oncolytic virus in treatment of tumors, particularly tumors insensitive to the oncolytic virus.

The invention belongs to the technical field of medicines and particularly relates to a new function of micromolecular metabolin, namely glutamine. The micromolecule can improve the sensitivity of bacteria including drug-resistant bacteria to antibiotics so as to solve the problem of drug resistance of bacteria. The micromolecule provided by the invention has better effect and higher safety and operability compared with antibiotic which is applied to the medicament for resisting drug resistance of bacteria at present.

The invention belongs to the field of biological medicines, and relates to application of Bcl-xL inhibitor and oncolytic virus to preparation of anti-tumor medicines. It is found for the first time that Bcl-xL inhibitor can be used for preparing oncolytic virus anti-tumor synergist. The invention meanwhile relates to a pharmaceutical composition containing Bcl-xL inhibitor and oncolytic virus, a medicine suit containing Bcl-xL inhibitor and oncolytic virus, and application of Bcl-xL inhibitor and oncolytic virus to treatment of tumors, especially tumors not sensitive to oncolytic virus.

The invention belongs to the field of biomedicine and relates to synergistic antitumor drug, in particular to application of antitumor drug like DNA-PK (DNA-dependent protein kinase, DNA-PK) inhibitors and oncolytic viruses in preparing antitumor drug. It is found for the first time that the antitumor drug like the DNA-PK inhibitor with various targets can be used for preparing oncolytic virus antitumor synergists. The invention further relates to a drug composition containing the antitumor drug and the oncolytic viruses, drug sets comprising the antitumor drug and the oncolytic viruses and application of the antitumor drug and the oncolytic viruses in treating tumor, especially for tumor insensitive to the oncolytic viruses.

The invention relates to the field of design of medical apparatuses, and in particular to a fixed plateau type unicompartment knee prosthesis, which comprises a femoral condyle prosthesis, a fixed plateau mat and a tibial plateau prosthesis, wherein the cross section of the tibial plateau prosthesis is similar to a semicircle; a clamping groove is formed in the inner wall of the tibial plateau prosthesis; the fixed plateau mat is clamped in the clamping groove; the upper surface of the fixed plateau mat is a fixed plateau mat is a single-radius cambered surface which is relatively low in curvature; the femoral condyle prosthesis is of a single-radius spherical structure; and the femoral condyle prosthesis is placed on the fixed plateau mat. The product (the fixed plateau type unicompartment knee prosthesis) provided by the invention is strong in bearing capacity, and the product can guarantee stability of buckling and prevent injuries and pain of surrounding soft tissues; the designingmethod of the tibial plateau prosthesis comprises steps of CT scanning, data importing and measuring, data analyzing and designing the Chinese people's anatomical tibial plateau prosthesis, so that the designed tibial plateau prosthesis can conform more to a tibial anatomical structure of Chinese people; therefore, a bone coverage rate and bearing capacity of proximal tibia cortical bone to the plateau prosthesis are improved, a risk of fatigue fracture of the plateau prosthesis is reduced and a survival rate of the prosthesis is improved.

The invention discloses an application of POU5F1B in diagnosis, treatment, prognosis and relapse prediction of tumor. In the invention, it is found that the copy number and the expression level of the gene POU5F1B in various tumors are closely related to transfer, relapse, patient prognosis and dryness of the tumor cells. A research result proves that by means of high expression of the POU5F1B, formation of TIC is promoted and further the in-vivo tumorigenic capability of esophagus cancer cells is enhanced, thereby reducing the survival rate, and oppositely, by means of inhibition of the expression of the POU5F1B, the formation of the TIC is promoted and further the in-vivo tumorigenic capability of the esophagus cancer cells is reduced, thereby increasing the survival rate, so that it is obviously that by means of inhibition of the endogenous POU5F1B, the in-vivo tumorigenic capability of the esophagus cancer cells can be significantly reduced, thereby increasing the survival rate of patients, which proves that the POU5F1B can be used as a marker for diagnosis, treatment, prognosis and relapse prediction. An inhibitor of the POU5F1B has a great clinical application value in preparation of a drug composition for tumor, so that the invention provides a new drug and a new method for effective treatment of tumor.

The invention relates to a biomarker used for prognosis of lung cancer. 95 lung cancer prognosis specific genes are selected from 2738 lung cancer gene expression programming data from various countries through statistical analysis, wherein 85 of the selected genes are related to survival probability and postoperative relapse probability that reported for the first time. Furthermore, the 95 lung cancer prognosis specific genes are subjected to single-factor analysis, multi-factor analysis and survival curve analysis to finally accurately select seven representive genes. Clinical data in various countries proves that the gene markers can be very effectively used for predicting the survival probability and postoperative relapse probability of lung cancer, and according to this, lung cancer patiens are divided into low-, medium- and high-risk groups.

The invention provides a novel stilbene derivative. The novel stilbene derivative is a compound with a general formula I or general formula II shown as the specification, or is an acceptable salt formed by the compound with the general formula I or general formula II and an inorganic acid or organic acid. Specifically, in the general formula I or general formula II, the atom represented by X is hydrogen atom or halogen atom, the substituent group represented by R is C1-C6 alkyl, 1-6 membered heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, substituent C3-C6 cycloalkyl, 3-6 membered heterocycloalkyl, substituent 3-6 membered heterocycloalkyl, 5-18 membered aryl, substituent 5-18 membered aryl, 5-18 membered heteroaryl, and substituent 5-18 membered heteroaryl. The novel stilbene derivative has neurogenesis activity and low nerve cell toxicity.

The invention discloses the application of an ulcerative colitis biological marker and treatment target spot. According to the application of the ulcerative colitis biological marker and treatment target spot, it is found that the expression amount of a NOC4L protein in a mouse is related to ulcerative colitis, and the NOC4L protein can be used as the biological marker of the ulcerative colitis. It is further found that symptoms of the ulcerative colitis of a macrophagespecific knock-out NO4L mouse are improved, and the survival rate is higher. A new target spot for researching a novel medicament for treating the ulcerative colitis is provided, a detection target is further provided for the diagnosis of the ulcerative colitis, and the application prospect is good.

An N-trans-vitamin A acid ethylamide derivative is prepared through reaction between trans-vitamin A acid powder, phenol and phosphorus trichloride, stirring in nitrogen gas, extracting by ether, chromatography, and mass spectroscopy. It can regulate the fucosyltransferase and suppress liver cancer cell with lower poison, so it can be used to preparing antineoplastics.

The invention belongs to the technical field of biological medicine, and particularly relates to an application of compound amino acid in preparation of a medicine for improving sensitivity of bacteria to antibiotics. The experiments prove that the compound amino acid and the antibiotics are combined for use, so that the sensitivity of bacteria to the antibiotics can be improved, the antibiotics are promoted to enter bacterial cells, the content of the antibiotics in the cells is remarkably increased, and the sterilization effect of the antibiotics is improved, thereby reducing the survival rate of the bacteria and treating diseases caused by bacterial infection.

The invention discloses a preparation capable of improving sensibility of bacteria on antibiotics and relates to glycine and glucose. Because glycine serving as small molecules capable of improving the sensibility of bacteria on antibiotics achieves an effect of inhibiting drug-resistance bacteria, glycine can be applied to improve the sensibility of bacteria on antibiotics. Because glycine and glucose serving as small molecules capable of improving the sensibility of bacteria on antibiotics achieve an effect of inhibiting drug-resistance bacteria, glycine and glucose can be combined to be applied to improve the sensibility of bacteria on antibiotics. The preparation is composed of glycine, glucose and antibiotics in a mass ratio of 1:(0.01-100):(0.01-10). A usage amount of glycine is 0.1mg-1g / kg per time. After glycine is added, the survival rate of slow Edwardsiella drug-resistance bacteria treated by kanamycin is obviously decreased, meaning the sensibility of slow Edwardsiella drug-resistance bacteria to kanamycin can be improved.

The invention provides a bionic robotic fish cluster navigation simulation method based on the deep reinforcement learning technology, and relates to the technical field of multi-agent path navigation planning. The method comprises the following steps: firstly, constructing a 3D fish swarm environment model, and then constructing an agent model of a bionic robotic fish cluster in the 3D fish swarm environment; the intelligent agent model comprises a perception model, a movement model and a decision-making model; constructing a reward function of the fish swarm cluster, and introducing a curiosity mechanism into the reward function; constructing a distributed training framework of an agent model based on a curiosity mechanism and a PPO2 algorithm, and enabling an agent to obtain a behavior strategy in a learning mode; and finally, training an agent model based on the constructed distributed training framework to realize navigation simulation of the bionic robotic fish cluster. According to the method, a virtual fish school can learn reasonable fish school behaviors in a 3D environment, and the method is applied to bionic robot fish school navigation behaviors in the real world.

The invention provides a preparation jointly using glycine and amoxicillin, and relates to a micromolecule substance, such as glycine. The glycine can be used for improving the sensitivity of bacteriato penicillin antibiotics, such as amoxicillin; the glycine and glucose can be used for improving the sensitivity of bacteria to penicillin antibiotics, such as amoxicillin. The preparation jointly using the glycine and the amoxicillin is prepared from the glycine and / or the glucose, and the penicillin antibiotics, such as amoxicillin. The preparation has the advantages that by adding the glycineand / or the glucose, the survival rate of edwardsiella tarda is obviously reduced when the edwardsiella tarda is treated by the amoxicillin, and the glycine and / or the glucose can improve the sensitivity of the edwardsiella tarda to the amoxicillin; after the glycine and / or the glucose is added, the survival rate of escherichia coli is obviously reduced when the escherichia coli is treated by theamoxicillin,, and the glycine and / or the glucose can improve the sensitivity of the escherichia coli to the amoxicillin.

The invention discloses an environment-friendly preservative. The environment-friendly preservative comprises the following components in parts by weight: 35-50 parts of triazole nucleoside carboxylicacid modified hyperbranched polylysine, 2-5 parts of choline borate, 0.5-1.5 parts of lecithin, 4-7 parts of graphene, 0.5-1.5 parts of sodium glycyrrhetate, 6-10 parts of an antiseptic Chinese herbal medicine extract, 1-2 parts of a celery extract, 1-2 parts of a Hamamelis virginiana extract, 10-20 parts of ethanol and 150-200 parts of deionized water. The invention also provides a preparation method of the environment-friendly preservative. The environment-friendly preservative disclosed by the invention has obvious preservative effect, diverse performance, wide range of wood rot bacteria and insects resistance, stable performance in the process of storage and transportation, and safe and environment-friendly use.

The invention discloses an application of a ubiquitin-binding enzyme E2 inhibitor as an anti-tumor synergist / drug resistance reversal agent of oncolytic virus for the first time. The ubiquitin-bindingenzyme E2 inhibitor can significantly enhance the oncolytic effect of oncolytic virus by inhibiting ubiquitin-binding enzyme E2. The compound Bay11-7082 for inhibiting the activity of the ubiquitin-binding enzyme E2 to act on tumor cells in cooperation with oncolytic virus, especially M1 virus, and experimental results show that Bay11-7082 can be cooperated with oncolytic virus to enhance the anti-tumor effect.

The invention discloses application of SATB1 to treatment of cutaneous T cell lymphomata. The invention discloses application of a product taking the following any one substance as a target to preparation of medicaments for preventing and / or treating cutaneous T cell lymphomata: (1) a protein shown in SEQ ID No.1; (2) a DNA molecule shown in SEQ ID No.2; (3) a DNA molecule shown in nucleotides from 1736th to 4024th beginning from the 5'-end in SEQ ID No.2. SATB1 protein is specifically expressed in CD30+ tumorous T cells in cutaneous T cell lymphomata, the expression up-regulation of the SATB1 protein plays a major role in attack and development of the cutaneous T cell lymphomata through promoting the cell cycle development, and SATB1 serving as a target has a bright application prospect in treatment of cutaneous T cell lymphomata.

The present invention relates to a method for treating a subject suffering from melanoma resistant by administering to said subject an inhibitor of NAMPT. Using a global metabolic profiling, inventors have showed that in addition to glycolysis, the BRAF inhibitor, PLX4032, promoted a complex metabolic rewiring of melanoma cells, including protein catabolism and fatty acid synthesis. Importantly, they observed that PLX4032 reduced the levels of nicotinamide adenine dinucleotide (NAD+), an important redox co-factor in numerous metabolic processes, including glycolysis, tricarboxylic acid cycle (TCA) cycle, glutamate metabolism and fatty acid betaoxidation. Pharmacological or genetic inhibition of NAMPT impaired melanoma cell growth, whereas the overexpression of NAMPT dampened the antiproliferative effect of PLX4032. In vivo, the inhibition of NAMPT also prevented the xenograft development of PLX4032-sensitive and -resistant melanoma cells, identifying NAMPT as a potential target for BRAFi-resistant melanomas.

The invention belongs to the field of chemistry, and specifically relates to N-all-trans retinamide derivatives, a preparation method thereof and an antitumor application thereof. The present invention adopts molecular simulation structure design, uses all-trans retinoic acid dry powder as raw material to react with benzene and phosphorus trichloride, and is prepared after synthesis and purification by stirring under nitrogen, ether extraction, chromatography, mass spectrometry analysis, etc., and the present invention derives The molecule has the following general structure. The present invention has been proved by experiments that it has an obvious regulating effect on α16 fucose glycosyltransferase, is less toxic than retinoic acid, has a strong inhibitory effect on liver cancer cells, and has the effect of significantly inhibiting the metastasis potential of liver cancer cells in nude mice, and can be prepared A new type of antineoplastic drug with high potential social benefits and application prospects. ∴

The invention provides an application of bergenin in preparation of a medicine for treating Klebsiella pneumoniae in vivo, and belongs to the technical field of biology and medicines. The invention proves that the bergenin can improve the cell survival rate reduction caused by Klebsiella pneumoniae infection, the cell oxidative damage caused by Klebsiella pneumoniae infection is improved, inflammatory response caused by Klebsiella pneumoniae infection is improved, lung injury caused by Klebsiella pneumoniae infection is improved, Klebsiella pneumoniae infection of lung is reduced, phosphorylation of ERK, JNK and p38 is inhibited and phosphorylation of I kappa B and p65 is inhibited so that Klebsiella pneumoniae infection is treated. The application is beneficial to further development andutilization of bergenin.

The invention belongs to the technical field of animal husbandry, and in particular, relates to a Chinese herbal medicine-probiotic compound preparation for preventing and treating chicken coccidiosisand a preparing method thereof. The Chinese herbal medicine-probiotic compound preparation comprises the components in parts by weight: 30-45 parts by weight of a Chinese herbal medicine preparation,1.0-1.5 parts by weight of compound probiotics, 0.3-0.8 part by weight of oligosaccharides and 0.2-0.5 part by weight of enzyme preparations. The prepared Chinese herbal medicine-probiotic compound preparation for preventing and treating chicken coccidiosis can regulate the microecological balance of digestive tracts of chicken flocks, enhance the immunity of the chicken flocks, reduce the incidence of chicken coccidiosis, and reduce the dosage of antibiotics.

The invention relates to the field of gene extraction, in particular to a gene extraction plant root pretreatment device. The technical problem to be solved by the invention is to provide the gene extraction plant root pretreatment device. The gene extraction plant root pretreatment device comprises wheels, a lifting platform, stairs, a main root outlet, a concentric mud stripping device and a main root separation and collection device. The right side of the bottom in the frame is connected with the stairs located on the right side of the lifting platform. The beautifying function of the shrubfixing device is protected against damage under the condition that the shrubs which are difficult to fix by a common device are stably and rapidly fixed, root covering soil stripping is continuouslyand efficiently conducted under the condition that manual work is replaced for surrounding type controllable range and large-area separation of the root covering soil is not caused, and the root can be kept wet; the survival rate of the replanted trees is greatly improved, the main roots are exposed through one-time cutting and separation, and the situation that the survival rate of the replantedtrees is greatly reduced due to severe damage to the main roots caused by repeated cutting and pulling is avoided.

The present invention relates to the field of biological medicine and discloses an application of chrysophanol or its derivatives and oncolytic virus in preparing antitumor drugs. It is found for the first time that the chrysophanol or its derivatives can be used to prepare a synergistic agent with oncolytic virus in terms of anti-tumor effects. Also disclosed are a pharmaceutical composition comprising chrysophanol and oncolytic virus, a pharmaceutical package comprising chrysophanol and oncolytic virus, and the use of chrysophanol and oncolytic virus in treating tumors, in particular tumors insensitive to oncolytic virus.

The invention relates to the technical field of medical instruments, and discloses a medical plastic instrument collection box. According to the technical scheme, the medical plastic instrument collection box comprises two supporting plates and a bottom plate, the bottoms of the two supporting plates are fixedly connected with the top of the bottom plate, a refrigerating box is arranged at the topof the bottom plate, and a gauze collection box is connected to the top of the refrigerating box in a clamped mode; and an instrument collection box is clamped to the top of the gauze collection box,a cover plate is hinged to the top of the instrument collection box, the two sides of the refrigerating box, the two sides of the gauze collection box and the two sides of the instrument collection box are slidably connected with the supporting plates, upper baffles are hinged to the front face of the refrigerating box and the front face of the gauze collection box, and lower baffles are hinged to the bottoms of the upper baffles. Through the arrangement of clamping grooves and clamping blocks, when the lower baffles need to be opened, the lower baffles drive the upper baffles to move, the bottoms of the lower baffles are clamped to the proper clamping blocks, the upper baffles and the lower baffles are fixed, and medical staff can set the positions of the lower baffles according to needs.

The invention provides the methylation site of the ENO1 gene promoter region and its application in the preparation of a kit for early diagnosis and prognosis evaluation of esophageal cancer, belonging to the technical field of disease diagnosis and prognosis rating; the methylation site of the ENO1 gene promoter region As shown in SEQ ID No.1, the DNA of esophageal squamous cell carcinoma and adjacent normal samples was extracted, modified with bisulfite, and the methylation frequency of the CpG site in the promoter region of the ENO1 gene was detected by flight mass spectrometry. Immunohistochemical detection of ENO1 protein expression in esophageal squamous cell carcinoma and adjacent normal tissue samples; the study found that ENO1 gene promoter region was hypomethylated and ENO1 protein was highly expressed in esophageal squamous cell carcinoma, and patients with low methylation had poor prognosis , ENO1 can promote the glycolysis level of esophageal cancer cells, promote its proliferation and inhibit apoptosis; detect the methylation level of ENO1 gene for early diagnosis and prognosis evaluation of esophageal squamous cell carcinoma.

The invention discloses an application of polyphyllin II in preparation of a drug for enhancing the curative effect of cisplatin. Research shows that in a lung cancer cell strain H446, only the cell survival rate is slightly reduced when cisplatin is independently used, and the survival rate is greatly reduced after cisplatin is combined with polyphyllin II. Meanwhile, the combined index CI measured by combined application of multiple concentrations of the polyphyllin II and the cisplatin is lower than 1, it is indicated that the polyphyllin II can sensitize the cisplatin and improve the anti-tumor curative effect of the cisplatin. According to the application of polyphyllin II in preparation of the drug for enhancing the curative effect of cisplatin, the traditional Chinese medicine paris polyphylla is wide in source, the detailed in vitro activity test results show that the polyphyllin II extracted and separated from a plant can effectively improve the drug resistance of cisplatin and improve the antitumor activity of the cisplatin when the polyphyllin II is combined with the first-line chemotherapeutic drug cisplatin.

The invention relates to the technical field of medicines for treating the hydatid disease, and particularly relates to application of an insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of a medicine for treating the cystic hydatid disease. The invention discloses the application of the BMS536924 in preparation of the medicine for treating the cystic hydatid disease for the first time. In-vivo and in-vitro experimental data shows that the BMS536924 is an efficient medicine molecule for resisting to the hydatid disease; the insulin-like growth factor 1 receptor inhibitor BMS536924 has remarkable treatment effects on the cystic hydatid disease, and the treatment effects are superior to those of an albendazole metabolite, i.e., albendazole sulfoxide; the medicine effect of the BMS536924 and ABZSO combined use is better than those of single administration of the BMS536924 and the ABZSO; and meanwhile, compared with the dosage of the single albendazole sulfoxide, the dosage of the BMS536924 combined albendazole is reduced by 1 / 4 to 1 / 2, so that the dosage and the drug resistance are greatly reduced, and a very good treatment effect is achieved.